Mefloquine hydrochloride

An antimalarial drug.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status

Used to treat other disease

Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Mefloquine is an antimalarial drug possibly acting on phospholipids forming toxic complexes with free heme in erythrocytic stage plasmodia (DrugBank).

Mefloquine hydrochloride on PubChem
Mefloquine hydrochloride on Wikipedia


Marketed as

MEFLOQUINE HYDROCHLORIDE or in a fixed-dose with Artesunate


Structure image - Mefloquine hydrochloride


Supporting references

Link Tested on Impact factor Notes Publication date
Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model.
Similar viruses

Two libraries of 2406 clinically approved drugs were screened for their ability to inhibit cytopathic effects on Vero E6 cells by GX_P2X (2019-nCoV related) infection

The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators
VERO E6 cell cultures May/21/2020
Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
Preprint In silico
VERO E6 cell cultures

synergistic effect in combination with rupintrivir

Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
Small molecule In vitro Screening
Vero cells 5.09 Nov/25/2020
Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate
Small molecule In vitro
VERO E6 cells; IHUMI-3 SARS-CoV-2 strain 3.20

Manifested strong inhibitory activity on SARS-CoV-2 in vitro when present at expected maximum blood concentration (fixed-dose with artesunate).

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate
Calu-3 human airway epithelial cells

higher IC50 value in Calu-3 cells than VERO E6 cells

Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo
Small molecule Animal model
BALB/c mice; A549 lung adenocarcinoma cells expressing ACE2; Vero E6 cells; SARS-CoV-2 strain MA15 4.32

Inhibits the production of infectious viral particles in vitro and decreases viral gene RNA levels.

Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation
Small molecule In vitro
Vero E6 cells; SARS-CoV-2 IHUMI-3 strain 4.59

The antimalarial drug inhibited SARS-CoV-2 in vitro at IC50 and IC90 similar to the concentrations reached during oral antimalarial treatment.

Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection
3CLpro PapainLpro Enzyme assay Animal model In vitro In silico
in silico; in vitro enzyme assay; Vero E6 cells; golden Syrian hamsters; SARS-CoV-2 clinical isolate hCoV-19/Taiwan/4/2020 9.41

Inhibited SARS-CoV-2 infection in Vero E6 cells. Oral administration preceding viral challenge significantly decreased lung viral loads in golden Syrian hamsters. 


AI-suggested references